Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Objective.—To evaluate the efficacy and safety of topiramate (100 mg/day) compared with placebo for the treatment of chronic migraine. Methods.—This was a randomized, placebo‐controlled, parallel‐group, multicenter study consisting of 16 weeks of double‐blind treatment. Subjects aged 18 to 65 years with 15 or more headache days per month, at least half of which were migraine/migrainous headaches, were randomized 1:1 to either topiramate 100 mg/day or placebo. An initial dose of topiramate 25 mg/day (or placebo) was titrated upward in weekly increments of 25 mg/day to a maximum of 100 mg/day (or to the maximum tolerated dose). Concomitant preventive migraine treatment was not allowed, and acute headache medication use was not to exceed 4 days per week during the double‐blind maintenance period. The primary efficacy endpoint was the change from baseline in the mean monthly number of migraine/migrainous days; the change in the mean monthly number of migraine days also was analyzed. A fixed sequence approach (ie, gatekeeper approach) using analysis of covariance was used to analyze the efficacy endpoints. Assessments of safety and tolerability included physical and neurologic examinations, clinical laboratory parameters, and spontaneous reports of clinical adverse events. Results.—The intent‐to‐treat population included 306 (topiramate, n = 153; placebo, n = 153) of 328 randomized subjects who provided at least 1 efficacy assessment; 55.8% of the topiramate group and 55.2% on placebo were trial completers. The mean final topiramate maintenance dose was 86.0 mg/day. The mean duration of therapy was 91.7 days for the topiramate group and 90.6 days for the placebo group. Topiramate treatment resulted in a statistically significant mean reduction of migraine/migrainous headache days (topiramate −6.4 vs placebo −4.7, P = .010) and migraine headache days relative to baseline (topiramate −5.6 vs placebo −4.1, P = .032). Treatment‐emergent adverse events occurred in 132 (82.5%) and 113 (70.2%) of topiramate‐treated and placebo‐treated subjects, respectively, and were generally of mild or moderate severity. Most commonly reported adverse events in the topiramate group were paresthesia (n = 46, 28.8%), upper respiratory tract infection (n = 22, 13.8%), and fatigue (n = 19, 11.9%). The most common adverse events in the placebo group were upper respiratory tract infection (n = 20, 12.4%), fatigue (n = 16, 9.9%), and nausea (n = 13, 8.1%). Discontinuations due to adverse events occurred in 18 (10.9%) topiramate subjects and 10 (6.1%) placebo subjects. There were no serious adverse events or deaths. Conclusions.—Topiramate treatment at daily doses of approximately 100 mg resulted in statistically significant improvements compared with placebo in mean monthly migraine/migrainous and migraine headache days. Topiramate is safe and generally well tolerated in this group of subjects with chronic migraine, a burdensome condition with important unmet treatment needs. Safety and tolerability of topiramate were consistent with experience in previous clinical trials involving the drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorge, F., Simone, R. D., Marano, E., Nolano, M., Orefice, G., & Carrieri, P. (1988) · Cephalalgia · doi:10.1046/j.1468-2982.1988.0801001.x · Cited by 3,465
Goadsby, P. J. (2004) · Cephalalgia · doi:10.1111/j.1468-2982.2004.00711.x · Cited by 2,381
Migraine — Current Understanding and Treatment
Goadsby, P. J., Lipton, R. B., & Ferrari, M. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmra010917 · Cited by 1,918
Self-citationSilberstein, S. D. (2000) · Neurology · doi:10.1212/wnl.55.6.754 · Cited by 1,360
Self-citationNew Appendix Criteria Open for a Broader Concept of Chronic Migraine
Olesen, J., Bousser, M.-G., Diener, H.-C., Dodick, D., First, M., Goadsby, P., Göbel, H., Lainez, M., Lance, J., Lipton, R., et al. (2006) · Cephalalgia · doi:10.1111/j.1468-2982.2006.01172.x · Cited by 909
Self-citationTopiramate for Migraine Prevention<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Brandes, J. L. (2004) · JAMA · doi:10.1001/jama.291.8.965 · Cited by 653
Self-citationThe International Classification of Headache Disorders (2nd ed.)
Westerhuis, P. (2004) · manuelletherapie · doi:10.1055/s-2004-813350 · Cited by 650
An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score
Stewart, W. F., Lipton, R. B., Whyte, J., Dowson, A., Kolodner, K., Liberman, J. N., & Sawyer, J. (1999) · Neurology · doi:10.1212/wnl.53.5.988 · Cited by 621
Self-citationClassification of daily and near-daily headaches: Field trial of revised IHS criteria
Silberstein, S. D., Lipton, R. B., & Sliwinski, M. (1996) · Neurology · doi:10.1212/wnl.47.4.871 · Cited by 611
Self-citationTopiramate in Migraine Prevention: Results of a Large Controlled Trial
Silberstein, S. D. (2004) · Archives of Neurology · doi:10.1001/archneur.61.4.490 · Cited by 529
Self-citationFeatures of medication overuse headache following overuse of different acute headache drugs
Limmroth, V., Katsarava, Z., Fritsche, G., Przywara, S., & Diener, H.-C. (2002) · Neurology · doi:10.1212/wnl.59.7.1011 · Cited by 391
Transformed or Evolutive Migraine
Mathew, N. T., Reuveni, U., & Perez, F. (1987) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.1987.hed2702102.x · Cited by 389
Self-citationDiener, H.-C., Tfelt-Hansen, P., Dahl�f, C., L�inez, M. J. A., Sandrini, G., Wang, S.-J., Neto, W., Vijapurkar, U., Doyle, A., Jacobs, D., et al. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0464-6 · Cited by 343
Self-citationSilberstein, S. D., & Lipton, R. B. (2000) · Current Opinion in Neurology · doi:10.1097/00019052-200006000-00008 · Cited by 295
Self-citationBigal, M. E., Rapoport, A. M., Lipton, R. B., Tepper, S. J., & Sheftell, F. D. (2003) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2003.03068.x · Cited by 242
Self-citationMultiple testing in clinical trials
Bauer, P. (1991) · Statistics in Medicine · doi:10.1002/sim.4780100609 · Cited by 241
Topiramate in the Treatment of Chronic Migraine
Silvestrini, M., Bartolini, M., Coccia, M., Baruffaldi, R., Taffi, R., & Provinciali, L. (2003) · Cephalalgia · doi:10.1046/j.1468-2982.2003.00592.x · Cited by 162
Analgesic overuse among subjects with headache, neck, and low-back pain
Zwart, J. A., Dyb, G., Hagen, K., Svebak, S., Stovner, L. J., & Holmen, J. (2004) · Neurology · doi:10.1212/01.wnl.0000123262.96132.fc · Cited by 145
Bussone, G., Diener, H., Pfeil, J., & Schwalen, S. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00612.x · Cited by 143
Mathew, N. T. (1993) · Cephalalgia · doi:10.1177/0333102493013s1217 · Cited by 130
Self-citationMathew, N. T. (1993) · PubMed · Cited by 100
Self-citationEfficacy of Topiramate and Valproate in Chronic Migraine
Bartolini, M., Silvestrini, M., Taffi, R., Lanciotti, C., Luconi, R., Capecci, M., & Provinciali, L. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000192136.46145.44 · Cited by 83
Field Testing Alternative Criteria for Chronic Migraine
Bigal, M., Tepper, S. J., Sheftell, F., Rapoport, A. M., & Lipton, R. B. (2006) · Cephalalgia · doi:10.1111/j.1468-2982.2006.01128.x · Cited by 58
Self-citationWhen migraine progresses: transformed or chronic migraine
Bigal, M. E., & Lipton, R. B. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.3.297 · Cited by 41
Self-citationDiener, H., & Goadsby, P. J. (2003) · Neurological Disorders · doi:10.1016/b978-012125831-3/50196-9 · Cited by 1
Cited by
Aurora, S., Dodick, D., Turkel, C., DeGryse, R., Silberstein, S., Lipton, R., Diener, H., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364676 · Cited by 1,047
Self-citationDodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., Diener, H., & Brin, M. F. (2010) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2010.01678.x · Cited by 994
Self-citationDiener, H., Dodick, D., Aurora, S., Turkel, C., DeGryse, R., Lipton, R., Silberstein, S., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364677 · Cited by 960
Self-citationEFNS guideline on the drug treatment of migraine—revised report of an EFNS task force
Evers, S., Áfra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., & Sándor, P. S. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02748.x · Cited by 892
Ashina, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1915327 · Cited by 816
Metadata
- Authors
- Silberstein, S. D., Lipton, R. B., Dodick, D. W., Freitag, F. G., Ramadan, N., Mathew, N., Brandes, J. L., Bigal, M., Saper, J., Ascher, S., Jordan, D. M., Greenberg, S. J., Hulihan, J., & on behalf of the Topiramate Chronic Migraine Study Group
- Venue
- Headache: The Journal of Head and Face Pain
- Publisher
- Wiley
- Published
- 2007-02
- Volume
- 47
- Issue
- 2
- Pages
- 170-180
- ISSN
- 0017-8748 (ISSN-L)
- 1526-4610
- OpenAlex
- W2127042724
- Cited by
- 497
- References
- 25
- FWCI
- 21.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.